Search the Newsreel

LQDA|Liquidia Corp|Price:85.495|Chg%:-1.325

This article provides a comprehensive stock analysis of Liquidia Corp (LQDA) from TradingKey, highlighting that its fundamentals are strong with high growth potential, and its valuation is considered fairly valued within the Pharmaceuticals industry. Despite strong fundamentals and stock performance, technical indicators show the …

Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares of Stock

Liquidia's Chief Accounting Officer, Dana Boyle, sold 1,600 shares of the company's stock for $140,048 on July 27th, 2026. This sale, executed under a Rule 10b5-1 plan, reduced her stake by 0.94% and was done to cover tax withholding obligations. The company's shares are …

Executive stock sale at Liquidia Corp (NASDAQ: LQDA) tied to RSU tax coverage

Liquidia Corp Chief Business Officer Jason Adair sold 688 shares of common stock on July 27, 2026, at $87.53 per share. This sale was conducted under a Rule 10b5-1 plan to cover taxes related to the settlement of previously granted Restricted Stock Units (RSUs). …

Liquidia Corporation Q2 Results: Earnings date set for August 12, 2026

Liquidia Corporation announced it will release its second-quarter 2026 financial results on August 12, 2026. The biopharmaceutical company will host a live webcast at 8:30 a.m. ET to discuss its financial performance and provide a corporate update, focusing on products like YUTREPIA™ and the …

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

Liquidia Corporation announced it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss these results and provide a corporate update. Liquidia is a biopharmaceutical company focused …

Stephen Bloch Sells 75,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Director Stephen Bloch recently sold 75,000 shares of Liquidia (NASDAQ:LQDA) stock for approximately $6.0 million, reducing his ownership by 9.66%. The sale occurred when Liquidia shares were trading near their 12-month high, following a strong quarterly earnings report that exceeded analyst expectations. Liquidia currently …

Liquidia schedules 8:30 a.m. webcast for Aug. 12 results

Liquidia Corporation (Nasdaq: LQDA) announced it will report its second-quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update, with rebroadcast available for one year. …

Liquidia Corp (LQDA) Valuation: PE, PB & Fair Value Analysis

Liquidia Corp (LQDA) currently holds a valuation score of 6.12, placing it 146th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is 346.96, which is slightly below its recent high and significantly above its recent low. The company has not yet …

Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential

Buckley Capital Advisors, in its Q2 2026 investor letter, highlighted Liquidia Corporation (NASDAQ:LQDA) as a significant contributor to its portfolio, despite its substantial appreciation. The firm still sees over 50% upside, anticipating a favorable Yutrepia product ruling and potential acquisition. Liquidia is a biopharmaceutical …

Liquidia Corp (LQDA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Liquidia Corp (LQDA) has a current earnings forecast score of 8.50, ranking 33rd in the Pharmaceuticals industry. Analysts have an average price target of $47.00 for LQDA, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is $168.54 million, …

Liquidia (LQDA) Stock Still Looks Expensive As YUTREPIA Expansion Progresses

Liquidia Corp Director Dr. Stephen M. Bloch Executes Major Stock Sales in July 2026

Liquidia Corp Director Dr. Stephen M. Bloch executed significant sales of common stock on July 22 and July 23, 2026. This insider trading activity is important for investors tracking company stock performance and internal movements. The article highlights the need for investors to monitor …

Liquidia Corporation (LQDA) Options Chain

This page provides detailed options chain data for Liquidia Corporation (LQDA) with an expiration date of August 28, 2026. It lists various call and put options, including strike prices, last trade dates, last prices, bid/ask, change, volume, open interest, and implied volatility. The article …

Liquidia Corp (LQDA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Liquidia Corp (LQDA)'s dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article lists current stock information including …

Liquidia Corp (LQDA) affiliate sells 200,000 shares in indirect insider trade

Liquidia Corp director Stephen M. Bloch reported indirect open-market sales of 200,000 common stock shares on July 22-23, 2026, executed by Canaan VIII L.P. The shares were sold at weighted average prices ranging from $87.16 to $90.90 per share, totaling approximately $17.79 million. Bloch …

LQDA|Liquidia Corp|Price:89.175|Chg%:+0.145

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's lead product candidate, YUTREPIA, utilizes its proprietary PRINT technology for enhanced drug …

Liquidia stock price target raised to $130 by H.C. Wainwright

H.C. Wainwright has significantly increased its price target for Liquidia Technologies (NASDAQ:LQDA) to $130 from $75, maintaining a Buy rating. This upgrade follows a recent court order regarding a patent dispute and strengthened conviction that Liquidia's YUTREPIA will become a leading treatment for pulmonary …

Liquidia Corp (LQDA) Fundamental & Financial Data

This page provides fundamental and financial data for Liquidia Corp (LQDA), listed on NASDAQ. It includes current stock price, market capitalization, volume, dividend yield, key financial ratios, and recent news headlines related to LQDA and other trending stocks. The information also features a section …

LQDA Maintains Buy Rating -- Price Target Raised to $130.00 by H

HC Wainwright & Co. has reiterated a Buy rating on Liquidia (LQDA), increasing its price target from $75.00 to $130.00, signaling strong confidence in the biopharmaceutical company's growth potential. While GuruFocus indicates LQDA is undervalued by 63.0% based on its GF Value™ of $239.45, …

Insider Decision: Stephen M Bloch Offloads $6.29M Worth Of Liquidia Stock

Stephen M. Bloch, a Board Member at Liquidia (NASDAQ: LQDA), recently sold 78,596 shares of company stock totaling $6.29 million, as disclosed in an SEC filing. This insider sale occurred on July 22, 2026, with Liquidia's stock trading at $86.05 at the time. The …

Liquidia director Stephen Bloch sells $6.28m in LQDA stock

Liquidia director Stephen Bloch sold approximately $6.28 million worth of LQDA stock in multiple transactions on July 20 and 21, 2026, with prices ranging from $79.5518 to $80.6576 per share. This sale follows a significant 390% surge in LQDA stock over the past year, …

Liquidia Corp (LQDA) director-linked fund sells 78,596 shares

Canaan VIII L.P., an investment fund associated with Liquidia Corp director Stephen M. Bloch, sold a total of 78,596 shares of Liquidia common stock between July 20-21, 2026. The sales were conducted as open-market transactions with weighted-average prices ranging from approximately $79.55 to $80.66. …

Julien Nono-Womdim's Top Picks: Regal Rexnord, Clean Harbors & Liquidia

Julien Nono-Womdim, Vice President and Equity Analysis at Goodreid Investment Council, has shared his top stock picks. His current recommendations for investors are Regal Rexnord, Clean Harbors, and Liquidia. The article also lists several other video segments featuring his past picks and market outlook, …

Liquidia Corp (LQDA) CHRO sells 7,864 shares in tax-related trade

Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 7,864 common shares on July 13, 2026, for approximately $71.40-$71.50 per share. These sales, conducted under a pre-established Rule 10b5-1 plan, were primarily to cover tax obligations arising from the settlement of previous RSU and …

Liquidia Corp (LQDA) CFO sells shares under 10b5-1 tax plan

Liquidia Corp's CFO and COO, Michael Kaseta, sold 20,430 shares of common stock on July 13, 2026, for approximately $1.46 million, following the exercise of 12,879 performance stock units on July 10, 2026. These sales were conducted under a Rule 10b5-1 plan to cover …

Liquidia Corp (NASDAQ: LQDA) GC sells 14,738 shares after PSU vesting

Liquidia general counsel Russell Schundler sold 14,738 shares of the company's common stock on July 13, 2026, at prices of $71.52 and $71.39 per share. These sales were conducted under a pre-arranged Rule 10b5-1 plan to cover tax obligations following the vesting and exercise …

Liquidia general counsel sells $1.05m in stock, priced $71.39-$71.52 By Investing.com

Liquidia Corp's General Counsel, Russell Schundler, sold 14,738 shares of company stock worth over $1 million at prices between $71.39 and $71.52. These sales, executed on July 13, 2026, were primarily to cover taxes related to the vesting of restricted and performance stock units. …

Liquidia Corp’s CHRO Sarah Krepp sells $562,360 in shares By Investing.com

Liquidia Corp's CHRO, Sarah Krepp, sold 7,864 shares totaling $562,360 through a Rule 10b5-1 plan to cover taxes on vested restricted and performance stock units. This sale follows a significant 427% surge in Liquidia's stock over the past year. Despite the sale, Krepp still …

Liquidia Corp (LQDA) CMO sells 9,926 shares after PSU conversions

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, exercised performance stock units and subsequently sold 9,926 common shares of LQDA. The sales, executed on July 13, 2026, under a Rule 10b5-1 plan, were primarily to cover tax obligations arising from the settlement of previously granted …

Liquidia Corp (LQDA) officer sells 1,185 shares in 10b5-1 tax sale

Liquidia Corp's Chief Development Officer, Sanjeev Khindri, sold 1,185 shares of the company's common stock on July 13, 2026, in two open-market transactions at prices of $71.52 and $71.39 per share. These sales, totaling approximately $85,000, were conducted under a Rule 10b5-1 plan to …

Liquidia CAO Dana Boyle sells 9,002 shares for $643,739

Liquidia's Chief Accounting Officer, Dana Boyle, sold 9,002 shares of LQDA stock for approximately $643,739 on July 13, 2026. These sales, executed under a Rule 10b5-1 plan, primarily covered taxes related to vesting restricted stock units. Despite Boyle's sales, Liquidia's stock has seen a …

Liquidia Corp (LQDA) CBO sells 7,863 shares after award vesting

Liquidia Corp's Chief Business Officer, Jason Adair, sold 7,863 common shares for approximately $71.40–$71.52 per share on July 13, 2026. This sale was conducted under a Rule 10b5-1 plan to cover taxes associated with the vesting of restricted and performance stock units that were …

Liquidia Corp CDO Khindri sells $84,740 in stock

Sanjeev Khindri, Chief Development Officer at Liquidia Corp (NASDAQ:LQDA), sold 1,185 shares totaling $84,740 on July 13, 2026. These sales were pre-arranged under a Rule 10b5-1 trading plan to cover tax obligations from vested restricted stock units. Despite the sale, which followed a significant …